Navigation Links
Alfacell Provides ONCONASE(R) NDA Submission Update
Date:12/5/2008

SOMERSET, N.J., Dec. 5 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today reported that the U.S. Food and Drug Administration (FDA) has scheduled a pre-NDA meeting date at the end of January 2009 for discussion of the company's planned submission of the final components of the ONCONASE rolling New Drug Application (NDA) for the treatment of unresectable malignant mesothelioma (UMM) patients. The pre-NDA meeting is an important step to complete prior to the planned submission of the final components of the ONCONASE rolling NDA for patients that have failed prior chemotherapy. Therefore, the final components of the rolling ONCONASE NDA will not be finalized until Alfacell receives guidance from the FDA at the pre-NDA meeting. Alfacell expects to provide an update on the planned completion of the rolling NDA within 48 hours of the conclusion of the pre-NDA meeting.

As the company has previously reported, the results of the preliminary statistical analysis of the data from the confirmatory Phase IIIb clinical trial for ONCONASE in patients suffering from UMM did not meet statistical significance for the primary endpoint of survival in UMM. However, a statistically significant improvement in survival was seen in the treatment of UMM patients who failed one prior chemotherapy regimen, a pre-defined primary data set for this sub-group of patients in the trial, which represents a currently unmet medical need.

Since receiving the results of this preliminary statistical analysis in late May 2008, the company engaged in an extensive and careful review of the data to submit to the FDA prior to the pre-NDA meeting. While preparations of materials for the pre-NDA meeting have taken more time than expected, by submitting the pre-NDA meeting request on October 3, 2008, Alfacell had anticipated that the pre-NDA meeting wo
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
2. Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
3. Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
4. Alfacells ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
5. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
6. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
7. Alfacell Corporation to Present at UBS Global Life Sciences Conference
8. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
11. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Boston Scientific Corporation (NYSE: ... announced agreement to purchase the Interventional business of ... Boston Scientific to offer physicians and healthcare systems ... challenging vascular conditions. The addition of ... technologies supports the Boston Scientific strategy to provide ...
(Date:9/2/2014)... DIEGO , Sept. 2, 2014  Volcano ... company focused on improving patient and economic outcomes ... innovative minimally invasive coronary and peripheral visualization, physiology ... be participating in the Morgan Stanley Healthcare conference ... by Scott Huennekens , president and chief ...
(Date:9/2/2014)... , Sept. 2, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has granted orphan drug ... hypertension. "The FDA Office of Orphan ... from sponsors to identify and designate drug candidates that ... evaluation and development of such products," said Craig ...
Breaking Medicine Technology:Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4
... SUNNYVALE, Calif., July 7, 2011 Cepheid (Nasdaq: ... for its 2011 second quarter ended June 30, 2011, on ... The company will host a management presentation at ... discuss the results.  To access the live webcast, please visit ...
... just three weeks after hearing oral argument, the First District ... judgment against Johnson & Johnson (NYSE: JNJ ) ... death case involving their Duragesic® fentanyl pain patch. ... in DiCosolo v. ALZA Corp, et al ., obtained ...
Cached Medicine Technology:Cepheid Schedules 2011 Second Quarter Financial Results Announcement and Webcast 2Heygood, Orr & Pearson: Court of Appeals Affirms $16.56 Million Judgment in Defective Fentanyl Patch Case 2Heygood, Orr & Pearson: Court of Appeals Affirms $16.56 Million Judgment in Defective Fentanyl Patch Case 3
(Date:9/2/2014)... September 02, 2014 The Dream2Walk Foundation along ... on Sept. 14th, 2014 during Spinal Cord Injury Awareness Month ... Lynn England, and Chuck Ligon. Linear Automotive will be there ... show. , Doors open at 2pm. The car show is ... one free pass to the concert. There will be trophies ...
(Date:9/2/2014)... Kathleen Doheny HealthDay ... The U.S. obesity epidemic is a driving force behind the ... study. Researchers looked at data from five national surveys ... increase in diabetes over time could be explained by factors ... U.S. adults. The investigators found that the prevalence of ...
(Date:9/2/2014)... By Steven Reinberg ... (HealthDay News) -- Stimulant medications -- such as Adderall, ... (ADHD) in children, won,t stunt their growth, a new ... final height as adults," said study researcher Dr. Slavica ... Clinic in Rochester, Minn. Katusic noted that results ...
(Date:9/2/2014)... HealthDay Reporter TUESDAY, Sept. 2, 2014 ... loss by blocking a certain nerve linked to appetite and ... patients. Using electric impulses to block the vagus nerve, ... suppress feelings of hunger. And, they did, just not to ... the nerve that connects the brain to the gut can ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- Drinking and marijuana may ... a new study suggests. Researchers analyzed 2007 to ... school seniors who said they had used alcohol or ... drinking alcohol was associated with more unsafe driving, damage ... about actions while under the influence of alcohol, especially ...
Breaking Medicine News(10 mins):Health News:Gas Monkey Hosts Concert in Dallas Benefiting Dream2Walk Foundation with Linear Automotive 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3Health News:ADHD Medications Won't Stunt Kids' Growth, Study Finds 2Health News:ADHD Medications Won't Stunt Kids' Growth, Study Finds 3Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 2Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 3Health News:Booze, Pot Bad for Teens in Different Ways, Study Suggests 2
... be making us hungrier, so we eat more, which in ... Yang and his colleagues at the Lawson Health Research Institute ... tissue can reproduce a hormone that stimulates fat cell production. ... way we think about and treat abdominal obesity. , Yang ...
... 16 Skanska USA Building Inc.,announced today that ... service the,growing Indiana construction markets. The announcement was ... Midwest operations., "Indiana is a strong construction ... "Skanska is an industry leader and after,working in ...
... Facing the ... Healthcare Industry, ... with U.S. News & World Report,hosted an exclusive panel discussion ... National Press Club in Washington, D.C.,The event, attended by Congressional ...
... with a faulty breast cancer gene could be at ... genes, according to research published this month in the ... University of Pennsylvania School of Medicine join an international ... 10,000 women carrying a BRCA1 or BRCA2 mutation for ...
... the source should lead to more effective vaccines, researchers say ... strains of virus that produce seasonal flu epidemics start in ... of the world, researchers report. , And by focusing on ... to improve their forecast of seasonal flu strains and develop ...
... Ala. - New clinical data showed some cancer patients ... AME-133v, said a researcher at the University of Alabama ... 15th during the 2008 annual meeting of the American ... 1 clinical trial data showed AME-133v had a potent ...
Cached Medicine News:Health News:Your belly fat could be making you hungrier 2Health News:Skanska Opens Indianapolis Office 2Health News:Siemens Addresses Cost vs. Value Issues In Healthcare and Technology 2Health News:Siemens Addresses Cost vs. Value Issues In Healthcare and Technology 3Health News:Breast cancer risk amplified by additional genes in combo with BRCA mutation 2Health News:Seasonal Flu Outbreaks Start in Asia: Study 2Health News:Seasonal Flu Outbreaks Start in Asia: Study 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: